Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discordant Humoral and T-Cell Response to mRNA SARS-CoV-2 Vaccine and the Risk of Breakthrough Infections in Women with Breast Cancer, Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Saavedra C, Vallejo A, Longo F, Serrano JJ, Fernández M, Gion M, López-Miranda E, Martínez-Jáñez N, Guerra E, Chamorro J, Rosero D, Velasco H, Martín A, Carrato A, Casado JL, Cortés A. Saavedra C, et al. Among authors: velasco h. Cancers (Basel). 2023 Mar 27;15(7):2000. doi: 10.3390/cancers15072000. Cancers (Basel). 2023. PMID: 37046661 Free PMC article.
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.
Cortés A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, Martin A, Chamorro J, Rosero D, Fernández M, Gion M, Martínez Jáñez N, Soria Rivas A, Alonso Gordoa T, Martínez Delfrade Í, Lage Y, López Miranda E, Olmedo ME, Reguera Puertas P, Gajate P, Molina Cerrillo J, Guerra Alia E, Fuentes Mateos R, Romero B, Rodríguez-Domínguez MJ, Vallejo A, Carrato A. Cortés A, et al. Among authors: velasco h. Eur J Cancer. 2022 May;166:229-239. doi: 10.1016/j.ejca.2022.02.017. Epub 2022 Mar 1. Eur J Cancer. 2022. PMID: 35316750 Free PMC article.
T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare workers with previous infection or cross-reactive immunity.
Casado JL, Haemmerle J, Vizcarra P, Rodriguez-Dominguez M, Velasco T, Velasco H, Centenera E, Romero-Hernandez B, Fernandez-Escribano M, Vallejo A. Casado JL, et al. Among authors: velasco t, velasco h. Clin Transl Immunology. 2021 Sep 8;10(9):e1341. doi: 10.1002/cti2.1341. eCollection 2021. Clin Transl Immunology. 2021. PMID: 34522381 Free PMC article.
BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity.
Vizcarra P, Haemmerle J, Velasco H, Velasco T, Fernández-Escribano M, Vallejo A, Casado JL. Vizcarra P, et al. Among authors: velasco t, velasco h. Vaccine. 2021 Dec 17;39(51):7367-7374. doi: 10.1016/j.vaccine.2021.10.074. Epub 2021 Nov 11. Vaccine. 2021. PMID: 34802792 Free PMC article.
Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity.
Vallejo A, Martín-Hondarza A, Gómez S, Velasco H, Vizcarra P, Haemmerle J, Casado JL. Vallejo A, et al. Among authors: velasco h. Front Microbiol. 2022 Feb 11;12:812729. doi: 10.3389/fmicb.2021.812729. eCollection 2021. Front Microbiol. 2022. PMID: 35222312 Free PMC article.
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.
Casado JL, Vizcarra P, Haemmerle J, Velasco H, Martín-Hondarza A, Rodríguez-Domínguez MJ, Velasco T, Martín S, Romero-Hernández B, Fernández-Escribano M, Vallejo A. Casado JL, et al. Among authors: velasco h. Vaccine X. 2022 Aug;11:100165. doi: 10.1016/j.jvacx.2022.100165. Epub 2022 May 2. Vaccine X. 2022. PMID: 35529539 Free PMC article.
65 results